Oruka Therapeutics, Inc. ORKA Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss?
- Oruka Therapeutics, Inc. (ORKA) reported debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss of $553K in Q1 2026.
- How has Oruka Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss changed year-over-year?
- Oruka Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss increased by 1102.2% year-over-year, from $46K to $553K.